This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Clinical Laboratories of Hawaii, LLP, Tissue-Typing and Cell Processing Lab
Clinical Laboratories of Hawaii, LLP, commonly referred to as CLH, is a leading provider of tissue-typing and cell processing services headquartered in the United States. Established in 1995, CLH has built a strong reputation across Hawaii and the Pacific region, specialising in immunogenetics and transplantation diagnostics. The laboratory offers a range of core services, including HLA typing, crossmatching, and cellular therapy processing, distinguished by their commitment to accuracy and rapid turnaround times. With state-of-the-art technology and a team of experienced professionals, CLH ensures high-quality results that support patient care and transplant success. Recognised for its excellence in the field, Clinical Laboratories of Hawaii has positioned itself as a trusted partner for healthcare providers, contributing significantly to advancements in transplant medicine and patient outcomes.
DitchCarbon Score
How does Clinical Laboratories of Hawaii, LLP, Tissue-Typing and Cell Processing Lab's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Clinical Laboratories of Hawaii, LLP, Tissue-Typing and Cell Processing Lab's score of 58 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Clinical Laboratories of Hawaii, LLP, Tissue-Typing and Cell Processing Lab currently does not have specific carbon emissions data available for the most recent year. As a merged entity, it inherits its climate commitments and emissions data from its parent organisation, Eurofins Scientific SE, at cascade level 4. While no absolute emissions figures are provided, Eurofins Scientific SE has established various climate initiatives, including Science Based Targets (SBTi) and participation in the Carbon Disclosure Project (CDP). However, specific reduction targets or achievements for Clinical Laboratories of Hawaii are not detailed in the available information. The organisation's commitment to sustainability aligns with industry standards, reflecting a broader trend among clinical laboratories to address climate change and reduce their carbon footprint. As they continue to integrate these initiatives, further details on their specific emissions and reduction strategies may emerge in the future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 72,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 155,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 311,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Clinical Laboratories of Hawaii, LLP, Tissue-Typing and Cell Processing Lab is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
